About Pasi A. Janne
Dr. Jänne is a highly qualified medical oncologist and researcher who specializes in lung cancer and targeted therapies. He received his MD and PhD from the University of Pennsylvania in 1996, and completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at Dana-Farber Cancer Institute (DFCI) in 2001.
He is currently the Director of the Lowe Center for Thoracic Oncology and the Scientific Director of the Belfer Center for Applied Cancer Science at DFCI.
Dr. Jänne is known for his research on the therapeutic relevance of oncogenic alterations in lung cancer, and was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations. He has led the development of therapeutic strategies for patients with EGFR mutant lung cancer. He has received several awards for his work, including the Fondation ARC Léopold Griffuel Prize in translational and clinical research in 2022, and the Outstanding Investigator Award from the National Cancer Institute (NCI) in 2018.
Dr. Jänne is Board certified in internal medicine and medical oncology, and his clinical interests include epidermal growth factor receptor targeted therapies, lung cancer, targeted therapies, and translational medicine. His primary location is Dana-Farber Cancer Institute, located at 450 Brookline Avenue, Boston, MA 02215. The phone number is 617-632-6190.